Livzon Pharmaceutical Group Details Board and Committee Structure

An update from Livzon Pharmaceutical Group ( (HK:1513) ) is now available.

Livzon Pharmaceutical Group has detailed the current composition of its board of directors, naming executive, non-executive, employee representative and independent non-executive members, with Zhu Baoguo serving as chairman and Tang Yanggang as vice chairman. The company also outlined the membership and chair roles across its five key board committees — Audit, Remuneration and Assessment, Nomination, Strategy, and Environmental, Social and Governance — clarifying responsibilities and reinforcing its corporate governance structure for investors and other stakeholders.

The designation of committee chairs, including leadership of the Audit Committee by independent director Bai Hua and of the ESG Committee by non-executive chairman Zhu Baoguo, underscores the company’s emphasis on oversight, strategic planning and sustainability. This governance disclosure provides greater transparency into how Livzon allocates decision-making and supervisory duties at board level, which may bolster confidence among shareholders and support the company’s positioning in the regulated pharmaceutical sector.

The most recent analyst rating on (HK:1513) stock is a Sell with a HK$22.99 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.

More about Livzon Pharmaceutical Group

Livzon Pharmaceutical Group Inc. is a China-based pharmaceutical company engaged in the research, development and production of medicines and related healthcare products. The group operates under a board structure that includes executive, non-executive, employee representative and independent non-executive directors, reflecting a governance framework typical of large listed pharmaceutical companies in China.

YTD Price Performance: 1.82%

Average Trading Volume: 679,748

Technical Sentiment Signal: Buy

Current Market Cap: HK$32.49B

Find detailed analytics on 1513 stock on TipRanks’ Stock Analysis page.